Peptide News Digest

#Lipid-Nanoparticles

2 stories

Research · View digest

Chongqing Team Adds Peptide Amphiphiles to Lipid Nanoparticles, Steering mRNA to the Spleen at Over 100 Times Liver Levels

Researchers at the Women and Children's Hospital of Chongqing Medical University built lipid nanoparticles containing two peptide amphiphiles, reporting in ACS Applied Materials & Interfaces. C16TAT, derived from a cell-penetrating peptide, improved mRNA delivery across several cell lines, while C16HA2, based on an endosome-disrupting peptide, changed the particles' charge and produced more than 100-fold higher mRNA expression in the spleen than in the liver in vivo. Particles with TAT attached to their surface worked in cells but performed worse in animals because they were less stable.

Research · View digest

WIRES Nanomedicine 2026 Review (Garland et al.): Peptide-Based Cancer Vaccines Materials, Targeting, and Delivery Strategies

A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.